Do you often get confused by sayings such as “whether eating too much of sweets leading to diabetes”? These are some of the myths build up by the misconception of the common people. Let us clear your doubts.
Medarex has intitiated phase 2 clinical trial of FG-3019 in patients with type 2 diabetes and advanced kidney disease. In this regard, Medarex will receive a milestone payment of an undisclosed amount from its licensing partner, FibroGen.
A Monash University study has proven a critical link between obesity and the onset of Type 2 diabetes, a discovery which could lead to the design of a drug to prevent the disease.
Diabetes, characterized by abnormal blood glucose levels, is a chronic disorder leading to several complications like cardiovascular disease, blindness, kidney disease, amputations etc. People with diabetes die at rates two to four times higher than those who do not have it.
Most recently, Australian researchers has found out that the two calculators which estimated CHD risk provided inappropriate results. Those are Framingham equation and United Kingdom Prospective Diabetes Study risk equation.
Diabetes is a disease in which the body cannot produce insulin or cannot use insulin to its full potential. It is characterized by high blood glucose levels. Insulin producing pancreatic beta cells are being destroyed by large concentration of inflammatory signals. This mechanism has been observed in type 1 diabetic patients.
Type 2 diabetes is the most common form of diabetes. Nearly 85 to 90 % of all the patients with the disease suffer from from type 2 diabetes. It is also referred as late onset diabetes and characterized by insufficient production of insulin by pancreatic ß-cells or insulin resistance (reduced target-tissue sensitivity to the effects of insulin).